

Financial news for RNN dated on 2019-06-04: 66 Biggest Movers From Yesterday

Financial news for RNN dated on 2019-06-03: 51 Stocks Moving In Monday's Mid-Day Session

Financial news for RNN dated on 2019-05-13: Rexahn Pharmaceuticals Q1 EPS \$(0.62) Beats \$(0.93) Estimate

Financial news for RNN dated on 2019-04-17: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., Apr. 17, 2019

Financial news for RNN dated on 2019-04-17: 40 Biggest Movers From Yesterday

Financial news for RNN dated on 2019-04-16: China Licensing Deal Sends Nanocap Rexahn Pharma Rocketing Higher

Financial news for RNN dated on 2019-04-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., Apr. 16, 2019

Financial news for RNN dated on 2019-04-16: Rexahn Pharmaceuticals shares are trading higher after the company announced a collaboration agreement with BioSense global. Rexahn will receive undisclosed upfront payment.

Financial news for RNN dated on 2019-04-16: Rexahn Pharma Announces a Collaboration Agreement with BioSense Global, Rexahn to Receive Undisclosed Upfront Payment

Financial news for RNN dated on 2019-04-15: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for RNN dated on 2019-04-10: Rexahn Reports Board Approved 1-For-12 Reverse Stock Split Effective Apr. 12, 2019

Financial news for RNN dated on 2019-03-08: Rexahn Pharma FY18 EPS \$(0.44) vs \$(0.92) In FY17

Financial news for RNN dated on 2019-03-04: Rexahn Reaches Target Enrollment In Phase 2a Clinical Trial Of RX-3117 In Combination With ABRAXANE In First-line Metastatic Pancreatic Cancer Patients

Financial news for RNN dated on 2019-02-19: Rexahn Highlights Presentation Of Updated Interim Data From Phase 2a Trial Of RX-3117 In Advanced Bladder Cancer At 2019 ASCO GU Symposium

Financial news for RNN dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for RNN dated on 2019-02-04: Rexahn Receives Notice of Allowance for US Patent Covering RX-3117 Use in a Broad Range of Tumor Types

Financial news for RNN dated on 2019-01-24: 54 Biggest Movers From Yesterday

Financial news for RNN dated on 2019-01-23: Mid-Afternoon Market Update: Crude Oil Down 1.8%; Waters Shares Gain On Upbeat Earnings

Financial news for RNN dated on 2019-01-23: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RNN dated on 2019-01-23: Mid-Day Market Update: Accuray Jumps Following Strong Q2 Results; Rexahn Pharmaceuticals Shares Slide

Financial news for RNN dated on 2019-01-23: Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Tops Q2 Estimates

Financial news for RNN dated on 2019-01-23: Rexahn Prices 10.75M Unit Offering At \$0.80/Share

Financial news for RNN dated on 2019-01-23: Rexahn Pharma shares are trading lower after the company announced a common stock offering.

Financial news for RNN dated on 2019-01-23: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RNN dated on 2019-01-22: Rexahn Reports Proposed Common Stock Offering, No Size Disclosed

Financial news for RNN dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for RNN dated on 2019-01-13: The Week Ahead In Biotech: Conferences,

PDUFA Dates And Clinical Trials

Financial news for RNN dated on 2018-12-12: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018

Financial news for RNN dated on 2018-12-06: Rexahn Had \$16M In Cash, Cash Equivalents, Investments As Of Dec. 2, 2018

Financial news for RNN dated on 2018-12-06: Rexahn Pharma To Cut Workforce To 10 Employees, Aiming To Reduce Overhead Cost

Financial news for RNN dated on 2018-11-05: Rexahn Pharmaceuticals Q3 EPS \$(0.17), Inline

Financial news for RNN dated on 2018-10-26: Rexahn Pharmaceuticals 13G Shows ~1.92M Share Stake From CVI Investments

Financial news for RNN dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for RNN dated on 2018-10-18: 46 Biggest Movers From Yesterday

Financial news for RNN dated on 2018-10-17: Mid-Afternoon Market Update: Vicor Climbs After Q3 Results; Revolution Lighting Technologies Shares Slide

Financial news for RNN dated on 2018-10-17: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for RNN dated on 2018-10-17: Mid-Day Market Update: Crude Oil Down 2.7%; vTv Therapeutics Shares Spike Higher

Financial news for RNN dated on 2018-10-17: Rexahn Pharmaceuticals shares are down 29.9% after the company earlier reported a \$7.5 million registered direct offering.

Financial news for RNN dated on 2018-10-17: Rexahn Reports \$7.5M Registered Direct Offering

Financial news for RNN dated on 2018-10-02: Rexahn Pharmaceuticals Announces Preliminary Safety And Efficacy Data From Ongoing Phase 2a Clinical Trial Of RX-3117 in Combination With Abraxane In Patients Newly Diagnosed With Metastatic Pancreatic Cancer

Financial news for RNN dated on 2018-08-21: Rexahn Reports Clinical Collaboration With Merck For Evaluation Of RX-5902 In Combo With KEYTRUDA For Triple-Negative Breast Cancer

Financial news for RNN dated on 2018-08-07: Rexahn Sends Investors Mid-Year Letter Reviewing Recent Progress, Clinical Plans

Financial news for RNN dated on 2018-08-06: Rexahn Pharmaceuticals Q2 EPS \$(0.12) Beats \$(0.18) Estimate

Financial news for RNN dated on 2018-07-31: Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

Financial news for RNN dated on 2018-07-31: B. Riley FBR Initiates Coverage On Rexahn Pharmaceuticals, Inc. Common Stock with Buy Rating, Announces \$7.50 Price Target

Financial news for RNN dated on 2018-06-06: 45 Biggest Movers From Yesterday

Financial news for RNN dated on 2018-05-21: 36 Biggest Movers From Friday

Financial news for RNN dated on 2018-05-15: Rexahn Pharma Reports Phase 2a Combo Study Of RX-3117, Abraxane In First-Line Metastatic Pancreatic Cancer Patients Advances To Second Stage

Financial news for RNN dated on 2018-05-07: Rexahn Pharmaceuticals Q1 EPS \$(0.07) Beats \$(0.14) Estimate

Financial news for RNN dated on 2018-03-12: Rexahn Pharma Reports FY EPS \$(0.92) vs \$(0.93) Est., No Sales

Financial news for RNN dated on 2018-02-12: Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Financial news for RNN dated on 2018-02-08: 19 Biotech Stocks With Clinical Trial Outcomes In February

Financial news for RNN dated on 2018-02-08: Rexahn Pharma Reports Collab With Zhejiang Haichang Biotech For Development Of RX-0201 For Treatment Of Hepatocellular Carcinoma

Financial news for RNN dated on 2018-01-29: Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902

Financial news for RNN dated on 2018-01-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for RNN dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for RNN dated on 2018-01-04: Rexahn Pharma Names Douglas Swirsky Pres, CFO

Financial news for RNN dated on 2018-01-04: Rexahn Pharmaceuticals Names Douglas Swirsky President, CFO

Financial news for RNN dated on 2017-12-29: 7 Notable Biotechs With Data Expected By Year's End

Financial news for RNN dated on 2017-12-11: Rexahn Pharma Presents New Preclinical Data On Supinixin: 'enhances the efficacy of immunotherapy in multiple preclinical models,' Showed 'potent activity against patient-derived TNBC tumors'

Financial news for RNN dated on 2017-11-08: Rexahn Pharma Reports Dosing Of First Patient In Phase IIa Trial Of Rx-3117 In Combo With Abraxane In Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Financial news for RNN dated on 2017-11-06: Rexahn Pharma Reports Q3 EPs \$(0.04) vs \$(0.13) In Same Qtr. Last Year

Financial news for RNN dated on 2017-10-16: 38 Biggest Movers From Friday

Financial news for RNN dated on 2017-10-13: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for RNN dated on 2017-10-13: Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge

Financial news for RNN dated on 2017-10-13: Mid-Morning Market Update: Markets Open Higher; Bank of America Profit Beats Expectations

Financial news for RNN dated on 2017-10-10: Rexahn Pharmaceuticals Receives Positive Opinion From EMA For Orphan Drug Designation For RX-3117

Financial news for RNN dated on 2017-10-06: Seaport Global Initiates Coverage On Rexahn Pharmaceuticals with Buy Rating, Announces \$13.00 Price Target

Financial news for RNN dated on 2017-09-01: Rexahn Pharma Announces Founder Chang Ahn To Retire From Board

Financial news for RNN dated on 2017-08-30: Rexahn Pharmaceuticals Receives New U.S. Patent for Supinixin, Patent Protection Extended until 2034

Financial news for RNN dated on 2017-08-07: Rexahn Pharma Says It Plans To Initiate More Clinical Studies With RX-3117 In Combo With Abraxane In 2H 2017

Financial news for RNN dated on 2017-08-07: Rexahn Pharmaceuticals Reports Q2 EPS \$0.04 vs \$(0.21) Est.

Financial news for RNN dated on 2017-07-10: Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117, Patent Protection for RX-3117 Extended until 2036

Financial news for RNN dated on 2017-06-07: Rexahn Reports \$10 Million Registered Direct Offering, Institutional Investors To Purchase 3.03M Shares of Stock

Financial news for RNN dated on 2017-06-04: Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer #ASCO17

Financial news for RNN dated on 2017-06-02: Mid-Morning Market Update: Markets Edge Hogher; Lululemon Beats Q1 Estimates

Financial news for RNN dated on 2017-05-12: Mid-Afternoon Market Update: Inpixon Drops Following Q1 Results; Technical Communications Shares Spike Higher

Financial news for RNN dated on 2017-05-12: 15 Biggest Mid-Day Gainers For Friday

Financial news for RNN dated on 2017-05-05: Rexahn Reports Effect of 1-for-10 Reverse Stock Split

Financial news for RNN dated on 2017-05-04: Rexahn Pharmaceuticals Reports Q1 EPS \$(0.09) vs \$(0.02) Est.

Financial news for RNN dated on 2017-04-13: Rexahn Reports 1-for-10 Reverse Stock Split

Financial news for RNN dated on 2017-04-11: Companies Holding Annual Shareholder Meetings Today Include: Rexahn Phamra, Bank Of New York Mellon, Lakeland Financial, Brocade Communications, & Bank Of South Carolina

Financial news for RNN dated on 2017-04-06: Benzinga's Top Upgrades, Downgrades For April 6, 2017

Financial news for RNN dated on 2017-04-06: Rodman & Renshaw Initiates Coverage On Rexahn Pharmaceuticals With Buy, Announces \$2 Price Target

Financial news for RNN dated on 2017-02-27: Rexahn Pharma Q4 FY 2016 EPS \$(0.04) vs \$(0.07) Est

Financial news for RNN dated on 2017-02-23: Rexahn Pharmaceuticals Doses First Patient in Phase IIa Trial of Supinoxin

Financial news for RNN dated on 2016-11-07: Rexahn Pharmaceuticals Reports Q3 EPS \$(0.01) vs. Prior Year Quarter \$(0.02)

Financial news for RNN dated on 2016-10-31: Rexahn Pharma Reports Received Notice of Allowance from US PTO for Patent Covering Manufacturing of RX-3117

Financial news for RNN dated on 2016-10-26: Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101

Financial news for RNN dated on 2016-09-14: Rexahn Reports \$6M Registered Direct Offering

Financial news for RNN dated on 2016-09-12: Rexahn Pharmaceuticals Begins Stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

Financial news for RNN dated on 2016-08-08: Rexahn Pharmaceuticals Reports Q2 EPS \$(0.01) vs. Est \$(0.02)

Financial news for RNN dated on 2016-07-11: Rexahn Pharmaceuticals Names Dr. Lisa Nolan Chief Business Officer

Financial news for RNN dated on 2016-06-06: Rexahn Pharmaceuticals Presents Phase 1/2 Data At ASCO For RX-3117 Supinoxin & Archexin That Show Continued Safety & Tolerability

Financial news for RNN dated on 2016-05-09: Rexahn Pharma Q1 EPS (\$0.02) vs (\$0.02) est

Financial news for RNN dated on 2016-04-20: Rexahn Will Present Trial Results for Archexin at AACR

Financial news for RNN dated on 2016-03-29: Rexahn Pharmaceutical Initiates Phase IB/IIA Trial Of RX-3117 In Pancreatic, Bladder Cancer Treatment

Financial news for RNN dated on 2016-03-24: Rexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast Cancer

Financial news for RNN dated on 2016-03-14: Rexahn Pharma Reports Q4 EPS \$(0.08) vs \$(0.03) Est.

Financial news for RNN dated on 2016-02-29: Sabby Management Reports 7.33% Stake in Rexahn in 13G

Financial news for RNN dated on 2016-02-26: Rexahn Announces \$5 Million Registered Direct Offering

Financial news for RNN dated on 2016-02-08: Rexahn Pharma Finishes Stage 1, Begins Stage 2 Enrollment Of Archexin Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma

Financial news for RNN dated on 2016-01-11: Rexahn Pharmaceuticals' Archexin(r) Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study

Financial news for RNN dated on 2015-12-14: Rexahn Pharmaceuticals Reports New Data for Supinoxin Showing Potent Tumor Growth Inhibition

Financial news for RNN dated on 2015-11-06: Rexahn Announces \$7.0M Registered Direct Offering

Financial news for RNN dated on 2015-11-05: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin(R) at the 14th International Kidney Cancer Symposium

Financial news for RNN dated on 2015-11-03: Rexahn Reports Q3 Loss of \$0.02/Share

Financial news for RNN dated on 2015-09-28: UPDATE: Rexahn Says Results of Data form Supinoxin, RX-3117 Programs Showed Oral Administration of Supinoxin Appeared Safe, Well Tolerated with No Grade 3 or 4 Adverse Events, Only One Unrelated Grade 2 Event

Financial news for RNN dated on 2015-09-28: Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015

Financial news for RNN dated on 2015-08-10: Rexahn Pharma Reports Q2 Loss of \$0.02/Share vs Loss of \$0.03/Share Est.

Financial news for RNN dated on 2015-07-14: UPDATE: Shares of Rexahn Pharmaceuticals Rise 25% Premarket as Co Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

Financial news for RNN dated on 2015-07-14: Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

Financial news for RNN dated on 2015-06-09: Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Financial news for RNN dated on 2015-06-08: National Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program

Financial news for RNN dated on 2015-05-11: Rexahn Pharma Reports Q1 EPS \$(0.02) vs. Est. \$(0.03)

Financial news for RNN dated on 2015-04-21: New Report Shows Rexahn's Supinoxin Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model

Financial news for RNN dated on 2015-04-20: Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for Cancer Research Annual Meeting

Financial news for RNN dated on 2015-04-13: Rexahn Pharmaceuticals to Show Data on RX-3117 and Supinoxin(TM) at the 2015 American Association for Cancer Research Annual Meeting

Financial news for RNN dated on 2015-03-20: UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility

Financial news for RNN dated on 2015-03-20: MLV & Co Initiates Coverage on Rexahn Pharmaceuticals at Buy, Announces \$1.25 PT

Financial news for RNN dated on 2015-03-17: Rexahn Reports FY14 Loss from Operations \$0.11/Share, May Not Compare to Loss of \$0.02/Share Est.

Financial news for RNN dated on 2015-02-09: Rexahn Pharma Offers Publication of Preclinical Data for RX-5902 Showing Mechanism of Action

Financial news for RNN dated on 2015-02-04: Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer

Financial news for RNN dated on 2015-01-06: Rexahn Pharma Reports Publication of Preclinical Data for RX-3117 Showing Effectiveness Against Gemcitabine

Financial news for RNN dated on 2014-12-03: Rexahn Pharmaceuticals Appoints Richard Rodgers To Its Board of Directors

Financial news for RNN dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for RNN dated on 2014-09-24: Rexahn Announces FDA Orphan Drug Designation for RX-3117 for Treatment of Pancreatic Cancer

Financial news for RNN dated on 2014-09-16: Laidlaw & Co. Initiates Coverage on Rexahn Pharmaceuticals, Inc. at Buy, Announces \$3.50 PT

Financial news for RNN dated on 2014-09-03: Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

Financial news for RNN dated on 2014-08-14: Rexahn Pharmaceuticals, Inc. Reports Q2 EPS of \$0.00 vs \$(0.02) Est

Financial news for RNN dated on 2014-07-18: Rexahn Pharma Reports Update on Phase I Supinoxin Trial, Says Patient Enrollment On Schedule for Closing in Q4

Financial news for RNN dated on 2014-05-23: S-3 Filing from Rexahn Pharma Shows Registration for \$150M Securities Shelf

Financial news for RNN dated on 2014-04-21: Rexahn Presents Data from Preclinical Studies of RX-21102

Financial news for RNN dated on 2014-04-02: Rexahn Pharmaceuticals to Present Data at American Association for Clinical Research Annual Meeting

Financial news for RNN dated on 2014-03-24: Brinson Patrick Initiates Coverage on Rexahn Pharmaceuticals, Inc. at Outperform, Announces \$3.00 PT

Financial news for RNN dated on 2014-03-11: Mid Morning Gainers for March 11th, 2014

Financial news for RNN dated on 2014-03-11: Rexahn Reports Initial Results from Phase I Trial of Supinoxin for Solid Cancer Tumors

Financial news for RNN dated on 2014-02-26: Morning Movers for Feb. 26, 2014: ANIK, JAKK, ZAGG, PLUG, TASR, ANF Moving Higher, FST, UTIW, SEAC, FSLR, DWA Lower

Financial news for RNN dated on 2014-02-25: Rexahn Pharmaceuticals Shares Rise 8% After-Hours

Financial news for RNN dated on 2014-01-15: Rexahn Announces \$20M Registered Direct Offering

Financial news for RNN dated on 2014-01-14: Morning Market Losers

Financial news for RNN dated on 2014-01-13: Morning Market Movers

Financial news for RNN dated on 2014-01-09: Roth Capital Initiates Coverage on Rexahn Pharmaceuticals, Inc. at Buy, Announces \$3.00 PT

Financial news for RNN dated on 2013-09-30: Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117

Financial news for RNN dated on 2013-08-07: Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors

Financial news for RNN dated on 2013-07-24: Rexahn Announces \$5.7M Registered Direct Offering

Financial news for RNN dated on 2013-07-17: Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

Financial news for RNN dated on 2013-07-15: Rexahn Pharmaceuticals Announce IND Submission for RX-3117

Financial news for RNN dated on 2013-07-09: Rexahn Pharma Receives Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2013-07-09: Rexahn Pharma Receives Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2013-06-17: Rexahn Pharma Wins US Patent for Novel Anti-Cancer Compounds

Financial news for RNN dated on 2013-02-19: Rexahn Pharma Issues 2013 Goals

Financial news for RNN dated on 2013-01-22: Rexahn Pharma Names Peter Suzdak CEO, Says Chang Ahm to Remain Chairman

Financial news for RNN dated on 2012-12-28: UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Financial news for RNN dated on 2012-12-28: Benzinga's Top Initiations

Financial news for RNN dated on 2012-12-28: Burrill Initiates Coverage on Rexahn Pharmaceuticals, Inc. at Market Outperform, Announces \$1.00 PT

Financial news for RNN dated on 2012-12-17: Rexahn Pharma Expands Intellectual Property Related to Class of Anti-Cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2012-12-13: Rexahn, Teva Close Private Offer of 2.08M Shares for \$750K

Financial news for RNN dated on 2012-11-28: Teva Increases Stake in Rexahn Pharma

Financial news for RNN dated on 2012-11-21: Rexahn Issued Patent for Quinoxalinyll-piperazine Compounds

Financial news for RNN dated on 2012-09-26: Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2012-09-26: Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2012-08-28: Rexahn Rises Almost 50% on Positive Phase II Data for Archexin

Financial news for RNN dated on 2012-08-28: Rexahn Pharma Reports Positive Phase 2 Data for Archexin

Financial news for RNN dated on 2012-07-05: Benzinga's Microcap Movers for Thursday July 5, 2012

Financial news for RNN dated on 2012-07-02: Rexahn Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902

Financial news for RNN dated on 2012-05-08: Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA

Financial news for RNN dated on 2012-04-30: Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds

Financial news for RNN dated on 2012-03-20: Earnings Scheduled For March 20

Financial news for RNN dated on 2012-03-16: Earnings Scheduled For March 16

Financial news for RNN dated on 2012-03-13: Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117

Financial news for RNN dated on 2012-01-25: Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyll-Piperazine Compounds

Financial news for RNN dated on 2012-01-18: Benzinga's Microcap Movers for Wednesday January 18, 2012

Financial news for RNN dated on 2012-01-18: Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform

Financial news for RNN dated on 2012-01-18: Hearing Rodman & Renshaw Upgrades Rexahn Pharmaceuticals from Under Review to Market Perform

Financial news for RNN dated on 2012-01-18: Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors

Financial news for RNN dated on 2012-01-17: Rexahn Pharmaceuticals Provides Key Goals for 2012

Financial news for RNN dated on 2011-11-04: Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder

Financial news for RNN dated on 2011-10-12: Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds

Financial news for RNN dated on 2011-10-03: Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin

Financial news for RNN dated on 2011-09-28: Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer

Financial news for RNN dated on 2011-08-01: Al Jazeera English Launches in New York

Financial news for RNN dated on 2011-06-22: Rexahn Pharmaceuticals Completes Patient Enrollment in Serdaxin Phase IIb Clinical Trial for Major Depressive Disorder

Financial news for RNN dated on 2011-04-28: Companies with CEO Buys of Over 50k Shares in April 2011

Financial news for RNN dated on 2011-03-28: Trading Resumes: Rexahn Pharmaceuticals

Financial news for RNN dated on 2011-03-28: Rexahn to Raise \$10M in Registered Direct Offering

Financial news for RNN dated on 2011-03-28: Trading Halted: Rexahn Pharmaceuticals, News Pending

Financial news for RNN dated on 2011-03-07: Rexahn Announces CEO Transition to CSO

Financial news for RNN dated on 2011-02-28: Rexahn Pharmaceuticals Granted European Patent for New Quinoxalinyll-piperazine Compounds

Financial news for RNN dated on 2011-01-20: Wendy's/Arby's, BioLase: Small-Cap Winners

Financial news for RNN dated on 2010-12-20: Rexahn Awarded Patent in Japan

Financial news for RNN dated on 2010-10-26: Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study

Financial news for RNN dated on 2010-06-22: Midday's Biggest Gainers (NURO, RNN, RPC, BVF)

Financial news for RNN dated on 2010-06-22: Mid-Day Market Movers (RNN, VPF, BFSB, AHC)